Benefits
Subjective stress reduction in healthy adults
Clinical trials in healthy adults under stress show modest reductions in subjective stress scores with B. longum 1714 supplementation. Effects are consistent across trials but smaller than pharmaceutical anxiolytics — supportive rather than primary intervention.
Improved cognition under stress
Trials using cognitive tasks during stress exposure show improved performance with B. longum 1714 supplementation. Particularly relevant for work-related stress affecting concentration and memory.
EEG and neuroendocrine biomarkers
Mechanistic trials show measurable changes in EEG patterns and stress hormone profiles with B. longum 1714 supplementation. Biomarker evidence supports the gut-brain axis mechanism beyond self-report effects.
Sleep quality support
Trials in adults with stress-related sleep disruption show improvements in subjective sleep quality over weeks of supplementation. Effects secondary to stress reduction rather than direct sleep-promoting mechanism.
Gut-brain axis mechanism
B. longum 1714 modulates vagal signaling and gut-brain communication pathways. Mechanism distinct from generic probiotic effects — strain-specific compounds and metabolites mediate the mood and stress effects.
Single-strain evidence vs combination products
Most 'mood probiotic' products use multi-strain blends without strain-specific evidence. B. longum 1714 has dedicated single-strain trials, providing clarity about what's actually being supported by the evidence.
Mechanism of action
Gut-brain axis modulation (psychobiotic)
Vagal afferent signaling, short-chain fatty acid production, neurotransmitter precursor modulation, and immune-mediated effects all contribute to the proposed psychobiotic mechanism. Strain-specific effects are likely mediated through a combination of these pathways rather than any single mechanism.
HPA axis cortisol attenuation
Attenuated cortisol response to acute stress (cold pressor test) has been demonstrated. Quantitative endocrine evidence beyond self-report scales.
Hippocampal function modulation
Hippocampus-dependent visuospatial memory improvements suggest hippocampal function modulation. The hippocampus is central to HPA axis regulation and to stress-related cognitive effects.
Cortical theta and frontal midline EEG modulation
MEG data showed increased theta band power in frontal and cingulate cortex, alongside enhanced frontal midline EEG mobility. Convergent neurophysiological evidence across two methodologies.
Stress response regulation
Combined endocrine (cortisol) and subjective (anxiety, daily reported stress) evidence indicates broad stress-response regulation. Effect distinguishes from sedative-style mechanisms.
Strain specificity (1714 distinct from other B. longum)
B. longum 1714 has clinical evidence distinct from other B. longum strains (NCC3001, BL999, etc.). Probiotic effects are strain-specific, not species-specific — generic 'B. longum' supplements should not be assumed equivalent.
Clinical trials
Clinical evidence on Bifidobacterium longum 1714 (Zenflore™ / 1714-Serenitas™) for the indications and outcomes described.
Clinical population described in trial publication.
Allen AP et al. 2016 (Transl Psychiatry, doi:10.1038/tp.2016.191). University College Cork APC Microbiome Institute. Within-participants design in 22 healthy male volunteers, 1×10⁹ CFU/day for 4 weeks. Attenuated cortisol output and subjective anxiety to socially evaluated cold pressor test; reduced daily reported stress; subtle hippocampus-dependent visuospatial memory improvements; enhanced frontal midline EEG mobility. Multi-domain endpoint design rare among probiotics.
Wang H, Braun C, Murphy EF, Enck P (Am J Gastroenterol).
Clinical population described in trial publication.
Wang H, Braun C, Murphy EF, Enck P (Am J Gastroenterol). Randomized double-blind placebo-controlled trial in 40 healthy volunteers using magnetoencephalography during the Cyberball social stress paradigm. Increased theta band power in frontal and cingulate cortex (P<0.05) — direct brain activity modulation evidence.
NCT04925440 — 8-week quadruple-masked clinical trial in adults with low mood, 5×10⁹ CFU/day, Beck's Depression Inventory-II primary outcome.
Clinical population described in trial publication.
NCT04925440 — 8-week quadruple-masked clinical trial in adults with low mood, 5×10⁹ CFU/day, Beck's Depression Inventory-II primary outcome. Recently completed; outcome data publication awaited. PrecisionBiotics-sponsored. Emerging mood/depression evidence beyond healthy-volunteer studies.